Monte Rosa Company Insiders

GLUE Stock  USD 15.68  0.29  1.82%   
Monte Rosa employs about 147 people. The company is managed by 14 executives with a total tenure of roughly 343 years, averaging almost 24.0 years of service per executive, having 10.5 employees per reported executive. Evaluation of Monte Rosa's management performance can provide insight into the firm performance.

Insider Sentiment 50

 Impartial

 
Selling
 
Buying

Latest Trades

2025-03-24Chandra P LeoAcquired 10000 @ 5.84View
2024-10-28Versant Venture Capital Vi, L.Disposed 89990 @ 9.66View
Monitoring Monte Rosa's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private.

Monte Rosa Management Team Effectiveness

The company has return on total asset (ROA) of 0.0137 % which means that it generated a profit of $0.0137 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0928 %, meaning that it created $0.0928 on every $100 dollars invested by stockholders. Monte Rosa's management efficiency ratios could be used to measure how well Monte Rosa manages its routine affairs as well as how well it operates its assets and liabilities. As of January 3, 2026, Return On Tangible Assets is expected to decline to -0.16. In addition to that, Return On Capital Employed is expected to decline to -0.27. At present, Monte Rosa's Debt To Assets are projected to increase slightly based on the last few years of reporting.
As of January 3, 2026, Common Stock Shares Outstanding is expected to decline to about 56.3 M. In addition to that, Net Loss is expected to decline to about (102.5 M)
The majority of Monte Rosa outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Monte Rosa Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Monte Rosa Therapeutics. Please pay attention to any change in the institutional holdings of Monte Rosa as this could imply that something significant has changed or is about to change at the company.
 
Shares in Circulation  
First Issued
2020-03-31
Previous Quarter
82.2 M
Current Value
82.4 M
Avarage Shares Outstanding
51.5 M
Quarterly Volatility
19.3 M
 
Covid
Some institutional investors establish a significant position in stocks such as Monte Rosa in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Monte Rosa, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Monte Rosa Workforce Comparison

Monte Rosa Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,982. Monte Rosa holds roughly 147 in number of employees claiming about 4% of equities under Health Care industry.

Monte Rosa Profit Margins

The company has Profit Margin (PM) of 0.12 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (2.58) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.58.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.710.8
Fairly Down
Slightly volatile

Monte Rosa Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Monte Rosa insiders, such as employees or executives, is commonly permitted as long as it does not rely on Monte Rosa's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Monte Rosa insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.8333
5
6
 93,145 
 1,549,806 
2024-09-01
0.2
1
5
 30,000 
 1,701,389 
2024-06-01
0.8182
9
11
 252,600 
 824,178 
2023-09-01
0.25
1
4
 41,000 
 76,115 
2022-03-01
4.0
8
2
 898,850 
 116,120 
2021-06-01
1.3
78
60
 125,101,137 
 367,601,000 

Monte Rosa Notable Stakeholders

A Monte Rosa stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Monte Rosa often face trade-offs trying to please all of them. Monte Rosa's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Monte Rosa's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Markus MDCEO PresidentProfile
Filip MDChief OfficerProfile
Jennifer ChampouxVP OperationsProfile
Sharon TownsonChief OfficerProfile
Edmund DunnSenior ControllerProfile
John CastleChief ScientistProfile
Magnus DPHILSenior DevelopmentProfile
Philip JDGeneral CounselProfile
Andrew FunderburkSenior FinanceProfile
JD MBAChief OfficerProfile
Ajim CFAChief OfficerProfile
Owen WallaceChief OfficerProfile
Silvia BuonamiciVP BiologyProfile
Phil JDG CounselProfile
String symbol = request.getParameter("s");

About Monte Rosa Management Performance

The success or failure of an entity such as Monte Rosa Therapeutics often depends on how effective the management is. Monte Rosa management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Monte management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Monte management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.15)(0.16)
Return On Capital Employed(0.26)(0.27)
Return On Assets(0.15)(0.16)
Return On Equity(0.38)(0.36)
Please note, the presentation of Monte Rosa's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Monte Rosa's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Monte Rosa's management manipulating its earnings.

Monte Rosa Workforce Analysis

Traditionally, organizations such as Monte Rosa use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Monte Rosa within its industry.

Monte Rosa Manpower Efficiency

Return on Monte Rosa Manpower

Revenue Per Employee514.4K
Revenue Per Executive5.4M
Net Loss Per Employee494.6K
Net Loss Per Executive5.2M
Working Capital Per Employee1.5M
Working Capital Per Executive15.7M

Complementary Tools for Monte Stock analysis

When running Monte Rosa's price analysis, check to measure Monte Rosa's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monte Rosa is operating at the current time. Most of Monte Rosa's value examination focuses on studying past and present price action to predict the probability of Monte Rosa's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monte Rosa's price. Additionally, you may evaluate how the addition of Monte Rosa to your portfolios can decrease your overall portfolio volatility.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
CEOs Directory
Screen CEOs from public companies around the world
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators